http://orcid.org/0000-0002-6681-6315
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Melania Scarpa, Chiara Marchiori, Marco Scarpa & Ignazio Castagliuolo. (2021) CD80 expression is upregulated by TP53 activation in human cancer epithelial cells. OncoImmunology 10:1.
Read now
Read now
Sang-Soo Kim, Joe B. Harford, Manish Moghe, Antonina Rait & Esther H. Chang. (2018) Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. OncoImmunology 7:10.
Read now
Read now
Articles from other publishers (19)
Joe B. Harford. (2023) A Second Career for p53 as A Broad-Spectrum Antiviral?. Viruses 15:12, pages 2377.
Crossref
Crossref
Yongmei Gao, Li Wan, Mengyan Li, Bo Wang & Yuqing Ma. (2023) NRF2/HO-1 axis, BIRC5, and TP53 expression in ESCC and its correlation with clinical pathological characteristics and prognosis. The International Journal of Biological Markers 38:3-4, pages 174-184.
Crossref
Crossref
Xuanyu Zhang, Chao Shang, Xue Qiao & Yan Guo. (2023) Role and clinical significance of immunogenic cell death biomarkers in chemoresistance and immunoregulation of head and neck squamous cell carcinoma. Biomedicine & Pharmacotherapy 167, pages 115509.
Crossref
Crossref
Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, Guido Kroemer, Alberto Ciccia & Lorenzo Galluzzi. (2023) The DNA Damage Response and Inflammation in Cancer. Cancer Discovery 13:7, pages 1521-1545.
Crossref
Crossref
Xiaohui Pan, Wenxin Zhang, Hongjie Guo, Longsheng Wang, Honghai Wu, Ling Ding & Bo Yang. (2023) Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists. Biochemical Pharmacology 213, pages 115596.
Crossref
Crossref
Vikash Kansal, Andre J Burnham, Brendan L C Kinney, Nabil F Saba, Chrystal Paulos, Gregory B Lesinski, Zachary S Buchwald & Nicole C Schmitt. (2023) Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models. Journal for ImmunoTherapy of Cancer 11:1, pages e005940.
Crossref
Crossref
Sang-Soo Kim, Joe B. Harford, Manish Moghe, Caroline Doherty & Esther H. Chang. (2022) A Novel P53 Nanomedicine Reduces Immunosuppression and Augments Anti-PD-1 Therapy for Non-Small Cell Lung Cancer in Syngeneic Mouse Models. Cells 11:21, pages 3434.
Crossref
Crossref
Michihisa Kono, Shin Saito, Ann Marie Egloff, Clint T. Allen & Ravindra Uppaluri. (2022) The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations. Oral Oncology 132, pages 106012.
Crossref
Crossref
Joe B. Harford, Sang Soo Kim, Kathleen F. Pirollo & Esther H. Chang. (2022) TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19. Viruses 14:4, pages 739.
Crossref
Crossref
Hongpan Zhang, Zheng Huang, Yangguang Song, Zhihao Yang, Qi Shi, Kaige Wang, Zhiyu Zhang, Zheng Liu, Xiaobin Cui & Feng Li. (2021) The TP53-Related Signature Predicts Immune Cell Infiltration, Therapeutic Response, and Prognosis in Patients With Esophageal Carcinoma. Frontiers in Genetics 12.
Crossref
Crossref
Hui Qin Wang, Iain J. Mulford, Fiona Sharp, Jinsheng Liang, Sema Kurtulus, Gina Trabucco, David S. Quinn, Tyler A. Longmire, Nidhi Patel, Roshani Patil, Matthew D. Shirley, Yan Chen, Hao Wang, David A. Ruddy, Claire Fabre, Juliet A. Williams, Peter S. Hammerman, Jennifer Mataraza, Barbara Platzer & Ensar Halilovic. (2021) Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment. Cancer Research 81:11, pages 3079-3091.
Crossref
Crossref
Laure-Anne Teuwen, Laura P.M.H. De Rooij, Anne Cuypers, Katerina Rohlenova, Sébastien J. Dumas, Melissa García-Caballero, Elda Meta, Jacob Amersfoort, Federico Taverna, Lisa M. Becker, Nuphar Veiga, Anna Rita Cantelmo, Vincent Geldhof, Nadine V. Conchinha, Joanna Kalucka, Lucas Treps, Lena-Christin Conradi, Shawez Khan, Tobias K. Karakach, Stefaan Soenen, Stefan Vinckier, Luc Schoonjans, Guy Eelen, Steven Van Laere, Mieke Dewerchin, Luc Dirix, Massimiliano Mazzone, Yonglun Luo, Peter Vermeulen & Peter Carmeliet. (2021) Tumor vessel co-option probed by single-cell analysis. Cell Reports 35:11, pages 109253.
Crossref
Crossref
Jitka Fucikova, Oliver Kepp, Lenka Kasikova, Giulia Petroni, Takahiro Yamazaki, Peng Liu, Liwei Zhao, Radek Spisek, Guido Kroemer & Lorenzo Galluzzi. (2020) Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death & Disease 11:11.
Crossref
Crossref
Albert B. DeLeo & Ettore Appella. (2020) The p53 Saga: Early Steps in the Development of Tumor Immunotherapy. The Journal of Immunology 204:9, pages 2321-2328.
Crossref
Crossref
Catarina Roma-Rodrigues, Lorenzo Rivas-García, Pedro V. Baptista & Alexandra R. Fernandes. (2020) Gene Therapy in Cancer Treatment: Why Go Nano?. Pharmaceutics 12:3, pages 233.
Crossref
Crossref
Sang‐Soo Kim, Joe B. Harford, Manish Moghe, Tiffani Slaughter, Caroline Doherty & Esther H. Chang. (2019) A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma. International Journal of Cancer 145:9, pages 2535-2546.
Crossref
Crossref
Wei Li, Lin Xu, Jun Han, Kefei Yuan & Hong Wu. (2019) Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma. Frontiers in Oncology 9.
Crossref
Crossref
Minori Okubo, Maiko Miyazaki, Eiji Yuba & Atsushi Harada. (2019) Chondroitin Sulfate-Based pH-Sensitive Polymer-Modified Liposomes for Intracellular Antigen Delivery and Induction of Cancer Immunity. Bioconjugate Chemistry 30:5, pages 1518-1529.
Crossref
Crossref
Weimin Lin, Miao Chen, Le Hong, Hang Zhao & Qianming Chen. (2018) Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Frontiers in Oncology 8.
Crossref
Crossref